2025-10-11 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA), combining the provided data points with some interpretations. The report is structured with key figures first, followed by a more detailed analysis.

**Executive Summary**

Natera Inc. (NTRA) is a genetic testing company focused on reproductive health, oncology, and organ health. While NTRA's historical cumulative return lags behind the S&P 500 (VOO) by -22%, recent indicators suggest a potential short-term upward trend. Analyst ratings lean towards a "Buy" recommendation, but the company is still suffering losses, so investment should be considered carefully.

**1. Performance vs. S&P 500 (VOO)**

*   **NTRA Cumulative Return:** 75.99%
*   **VOO Cumulative Return:** 99.34%
*   **Spread (NTRA - VOO):** -22.0%
*   **Spread Range (Max: 174.8, Min: -88.5):**
    *   Current Relative Spread: 25.3 (Indicates the current spread is in the lower quartile of its historical range).

**Alpha, Beta Analysis Table**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :----- |
| 2015-2017  | -10.0%  | 70.1%   | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%   | 80.0%   | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%   | 80.0%   | 28.0%   | 1.0    | 4.6    |
| 2018-2020  | 186.0%  | 80.5%   | 163.0%  | 1.1    | 13.7   |
| 2019-2021  | 96.0%   | 80.5%   | 49.0%   | 1.6    | 12.8   |
| 2020-2022  | -77.0%  | 80.5%   | -76.0%  | 0.1    | 5.5    |
| 2021-2023  | -194.0% | 76.6%   | -195.0% | -1.1   | 8.6    |
| 2022-2024  | 8.0%    | 76.6%   | -13.0%  | -1.2   | 21.7   |
| 2023-2025  | 103.0%  | 76.6%   | 39.0%   | 0.1    | 23.4   |

*   **Analysis:** This table reveals high volatility. NTRA shows periods of significant outperformance (high Alpha) and underperformance (negative Alpha) compared to the market. Beta values fluctuate, indicating varying degrees of correlation with the market. Recent years (2021-2023) show significant underperformance.

**2. Recent Stock Price Movement**

*   **Current Price:** 170.26
*   **Last Market Data:** {'price': 170.2992, 'previousClose': 173.055, 'change': -1.59} (Slight decrease in the last session)
*   **5-day Moving Average:** 169.72
*   **20-day Moving Average:** 169.07
*   **60-day Moving Average:** 159.07

*   **Analysis:** The price is trading above all three moving averages, suggesting a short-term bullish trend. The close price compared to the previous one has fallen slightly

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 36.61 (Approaching oversold territory, suggesting a potential bounce)
*   **PPO:** 0.018 (Positive, indicating short-term bullish momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (6 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Spread Change:** 3.6 (+, Short-term increase)
*   **Expected Return:** -139.4% (Significant underperformance vs. S&P 500 for long-term investment)

*   **Analysis:** The MRI suggests a medium level of risk. The Hybrid Signal recommends allocating all available cash. A high negative expected return is a major cause for concern for long-term investing.

**4. Recent News & Significant Events**

*   **Positive Catalysts:** Enrollment in the EXPAND trial, publication of Signatera validation studies in testicular and uterine cancer, Wall street favorite stocks.
*   **Negative/Neutral:** Exploration of high-growth tech stocks (NTRA is mentioned alongside others, not a specific endorsement).

*   **Impact:** The news flow appears mixed but leans slightly positive with clinical trial progress and validation studies, which are crucial for a company in the diagnostic testing space.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.53)
*   **Opinions:** 19
*   **Target Price (Avg/High/Low):** 193.21 / 235.00 / 37.00
*   **Recent Rating Changes:** Not provided, so no trend analysis possible

*   **Analysis:** Strong analyst support with a "Buy" consensus and a significant average target price, suggesting potential upside. However, the wide range in target prices (37 to 235) indicates uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출    |
| :--------- | :---- | :------ |
| 2025-08-08 | -0.74 | 0.55 B$ |
| 2025-05-09 | -0.5  | 0.50 B$ |
| 2024-11-12 | -0.26 | 0.44 B$ |
| 2024-08-09 | -0.3  | 0.41 B$ |
| 2025-08-08 | -0.3  | 0.41 B$ |

*   **Analysis:** EPS is negative, indicating losses. Revenue is increasing over the observed period, which is a positive sign.

**6. Financial Information**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.55B | 63.41%        |
| 2025-03-31 | $0.50B | 63.12%        |
| 2024-12-31 | $0.48B | 62.94%        |
| 2024-09-30 | $0.44B | 61.79%        |
| 2024-06-30 | $0.41B | 58.83%        |

| Quarter    | Equity  | ROE      |
| :--------- | :-------- | :------- |
| 2025-06-30 | $1.25B  | -8.10%   |
| 2025-03-31 | $1.24B  | -5.40%   |
| 2024-12-31 | $1.20B  | -4.50%   |
| 2024-09-30 | $0.88B  | -3.60%   |
| 2024-06-30 | $0.84B  | -4.48%   |

*   **Analysis:** Revenue and profit margin are increasing, which is a strong positive. However, ROE is negative, reflecting the company's inability to generate profit from its equity.

**7. Overall Analysis and Conclusion**

NTRA presents a mixed picture. The company is growing revenue and has positive news flow regarding its clinical trials and product validation. Analyst ratings are favorable. However, the company is still loss-making, and historical performance has significantly lagged the S&P 500. While recent technical indicators suggest a short-term bullish trend, the negative expected return highlights long-term concerns.

**Recommendation:**

*   **Short-term:** Could be considered for a speculative buy, given the technical indicators and positive news, but with caution.
*   **Long-term:** The negative expected return and lack of profitability are significant red flags. Further due diligence is needed to assess the company's path to profitability and long-term growth potential before considering a long-term investment.

**Disclaimer:** This is an AI-generated analysis and not financial advice. Consult a qualified financial advisor before making any investment decisions.
